As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 3/04/15  Sanofi                            6-K         3/04/15    3:97K                                    Merrill Corp-MD/FA

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Report of a Foreign Private Issuer                  HTML     20K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     30K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML     22K 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the month of March 2015

 

Commission File Number: 001-31368

 

SANOFI

(Translation of registrant’s name into English)

 

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F x             Form 40-F o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):o

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes o                                   No x

 

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  82-

 

 

 

In March 2015, Sanofi issued the statements attached hereto as Exhibits 99.1 and 99.2 which are incorporated herein by reference.

 

Exhibit List

 

Exhibit No.		Description
Exhibit 99.1		Press release dated March 27, 2015: Toujeo® Receives Positive Opinion from the European Regulatory Authorities.
Exhibit 99.2		Press release dated March 26, 2015: Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo® .

 

2

 

Exhibit Index

 

Exhibit No.		Description
Exhibit 99.1		Press release dated March 27, 2015: Toujeo® Receives Positive Opinion from the European Regulatory Authorities.
Exhibit 99.2		Press release dated March 26, 2015: Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo® .

 

4